In 2010, Ariad declared end result from a phase I study of ponatinib in people with resistant and refractory Serious myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). For people with kidney issues: You might not have the capacity to very clear this drug out of your physique well. https://campbellv000ite2.dm-blog.com/profile